Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Britain Courts Anthropic Amid US Defense Department Dispute 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
BRIDGEWATER, N.J., Aug. 01, 2017 -- Valeritas Holdings, Inc. (NASDAQ:VLRX) announced today that John Timberlake, President and Chief Executive Officer, and Erick Lucera, Chief Financial Officer, are scheduled to present at the Wedbush PacGrow Healthcare Conference. The Company will also participate in the Drug Delivery Technologies Panel moderated in part by Tao Levy, Managing Director Medical Devices Equity Research.
| Event: | Wedbush Drug Delivery Technologies Panel | |
| Date: | Tuesday, August 15, 2017 | |
| Time: | 11:30 a.m. EDT | |
| Location: | New York, NY | |
| Event: | Wedbush PacGrow Healthcare Conference Company Presentation | |
| Date: | Wednesday, August 16, 2017 | |
| Time: | 9:10 a.m. EDT | |
| Location: | New York, NY | |
An audio webcast of the Company’s presentation will be available by visiting the investor relations section of the Valeritas website at www.valeritas.com. Replays of the presentation will be available for 90 days.
About Valeritas, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Investor Contact: Robert E. Flamm, Ph.D. / Brian Johnston The Ruth Group 646-536-7017 / 7028 [email protected] Or The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 [email protected] Media Contact: Kirsten Thomas / Cari Randall The Ruth Group 508-280-6592 / 646-536-7002 [email protected]
